Buscar Co

Buscar Co's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating minimal leverage and a strong equity position. The company's liquidity is moderate, with a current ratio of 1.6, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow is negative at -4.32 million USD, reflecting ongoing operational and capital expenditure demands. In terms of profitability, Buscar Co is currently unprofitable, with a return on equity of -3.16 and a return on assets of -2.64. These figures are below the industry median for diversified mining companies, indicating underperformance relative to peers. The company's operating and net income are both negative at -3.37 million USD, highlighting the need for operational improvements or cost reductions to achieve profitability. The company's business is diversified across natural resources, sustainable technologies, and pharmaceuticals. However, the financial data does not provide a breakdown of revenue by segment or geography, making it difficult to assess the concentration of revenue sources. The lack of detailed segment reporting limits the ability to evaluate the performance of each business line. Buscar Co's growth trajectory is uncertain, as the financial data does not include forward-looking revenue projections or historical growth rates. The company's negative free cash flow and operating losses suggest that it is not currently generating sufficient cash to support growth initiatives. Without a clear path to profitability or external financing, the company may face challenges in expanding its operations. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could impact its ability to meet short-term obligations. However, the low dilution risk suggests that the company is not likely to issue additional shares in the near term, preserving shareholder value. Recent events, as disclosed in the 10-K filing, include the management of gold mining operations in California's Plumas National Forest and the oversight of subsidiaries in bioplastics and pharmaceuticals. The company's focus on sustainable technologies and pharmaceuticals may provide long-term growth opportunities, but the current financial performance does not reflect these potential benefits.